An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease

N Engl J Med. 2021 Aug 26;385(9):856-857. doi: 10.1056/NEJMc2111960. Epub 2021 Jul 28.

Authors

Billy Dunn¹, Peter Stein¹, Robert Temple¹, Patrizia Cavazzoni¹

Affiliation

¹ U.S. Food and Drug Administration, Silver Spring, MD.

PMID: 34320283
DOI: 10.1056/NEJMc2111960

No abstract available

Publication types

Letter
Comment

MeSH terms

Alzheimer Disease* / drug therapy
Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
Humans

Substances

Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
aducanumab